Cure8 news brief
Positive Phase 3 data for Skyrizi in Crohn’s could affect treatment options and access if regulators expand the drug’s label and insurers update coverage; for patients and clinicians it may signal an additional biologic option becoming available in the future.
For patients on or awaiting post‑Humira therapies, the commercial success of Skyrizi influences availability and formulary decisions.
Adult patients with Crohn’s disease; patients on biologic therapy or awaiting new treatment options; gastroenterologists and IBD clinicians; researchers and industry watchers following immunology drug development.
AbbVie shares rose after the company released Phase 3 AFFIRM results for subcutaneous Skyrizi in Crohn’s disease; reporters and investors see the readout as confirmation of AbbVie’s post‑Humira growth strategy centered on Skyrizi and Rinvoq.
The piece is financial-news coverage emphasizing market and revenue implications; it does not present trial design, efficacy or safety data from AFFIRM in the article text provided here.
If you want clinical details (efficacy endpoints, safety profile, regulatory plans), look for the primary trial report, a company press release with data tables, or peer‑reviewed publications rather than this market‑reaction story.
This article is market-focused and reports investor reaction; it does not provide trial results, safety data, or regulatory decisions. Seek the AFFIRM trial primary source, AbbVie press releases, or clinical publications for clinical details. The financial impact described reflects investor interpretation, not clinical guidance.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Phase III AFFIRM results suggest a subcutaneous risankizumab regimen may increase endoscopic remission in Crohn’s disease, which matters for patients and clinicians weighing biologic options and for regulatory approval...
This Phase 3 trial directly compares two IL-23–targeting biologic therapies in moderate-to-severe Crohn's disease with a 52-week deep remission endpoint, which could inform future treatment choices if results are...
This trial is testing risankizumab in children with moderate-to-severe Crohn’s disease to learn how the drug behaves in kids, whether it’s safe, and whether it reduces disease activity — information that could expand...
